CSBio CSBio

X
[{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunic Exercises Option to License Daiichi\u2019s IMU-856","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Daiichi Sankyo"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$481.0 million","upfrontCash":"$44.0 million","newsHeadline":"Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]

Find Novel Gastroenterology Drugs in Preclinical Development in JAPAN

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR® technology and structure-based drug design platform. The licensed products includes an advanced lead preclinical drug as well as multiple differentiated back-up compounds.

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: GSK

            Deal Size: $481.0 million Upfront Cash: $44.0 million

            Deal Type: Collaboration December 20, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The option and license agreement gives Immunic the exclusive rights to commercialization of IMU-856 in all countries.

            Lead Product(s): IMU-856

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Immunic Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY